Oppenheimer Boosts Pharvaris (NASDAQ:PHVS) Price Target to $38.00

Pharvaris (NASDAQ:PHVS) had its target price hoisted by Oppenheimer from $36.00 to $38.00 in a report released on Wednesday morning, Benzinga reports. They currently have an outperform rating on the stock.

Several other research firms also recently commented on PHVS. JMP Securities upped their price target on shares of Pharvaris from $49.00 to $50.00 and gave the company a market outperform rating in a research note on Thursday, April 11th. Wedbush decreased their price target on shares of Pharvaris from $35.00 to $31.00 and set an outperform rating on the stock in a research note on Thursday, May 9th. Finally, Morgan Stanley restated an overweight rating and issued a $34.00 price target on shares of Pharvaris in a research note on Monday, April 22nd. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of Moderate Buy and a consensus target price of $32.80.

Pharvaris Trading Down 2.1 %

NASDAQ:PHVS opened at $16.65 on Wednesday. Pharvaris has a one year low of $14.05 and a one year high of $33.00. The firm’s fifty day moving average price is $19.50 and its two-hundred day moving average price is $23.46.

Pharvaris (NASDAQ:PHVS) last released its quarterly earnings results on Wednesday, May 8th. The company reported ($0.56) EPS for the quarter, meeting the consensus estimate of ($0.56). On average, sell-side analysts forecast that Pharvaris will post -2.35 EPS for the current fiscal year.

Institutional Investors Weigh In On Pharvaris

Several institutional investors and hedge funds have recently bought and sold shares of the company. Walleye Capital LLC lifted its position in Pharvaris by 15.2% during the third quarter. Walleye Capital LLC now owns 81,017 shares of the company’s stock worth $1,691,000 after purchasing an additional 10,691 shares during the period. Hudson Bay Capital Management LP bought a new stake in Pharvaris during the third quarter worth about $812,000. Blackstone Inc. bought a new position in shares of Pharvaris in the fourth quarter worth about $2,805,000. Vivo Capital LLC bought a new position in shares of Pharvaris in the fourth quarter worth about $7,994,000. Finally, venBio Partners LLC lifted its holdings in shares of Pharvaris by 15.4% in the fourth quarter. venBio Partners LLC now owns 4,919,504 shares of the company’s stock worth $137,992,000 after acquiring an additional 654,832 shares during the last quarter.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.